Robert Niecestro
Overview
Explore the profile of Robert Niecestro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Umanath K, Niecestro R, Lewis J, Dwyer J
Expert Rev Endocrinol Metab
. 2019 Feb;
8(1):13-19.
PMID: 30731649
Ferric citrate (KRX-0502; Keryx Biopharmaceuticals, Inc., NY, USA) is a novel phosphate-binding agent presently in Phase III clinical development. Ferric citrate dissociates in the bowel lumen releasing the ferric ion...
2.
Umanath K, Greco B, Jalal D, McFadden M, Sika M, Koury M, et al.
Clin Nephrol
. 2017 Jan;
87 (2017)(3):124-133.
PMID: 28128726
Iron stores assuring optimal efficacy/safety for erythropoiesis are unknown in the dialysis population. Using multicenter trial data, we related safety profiles, erythropoiesis-stimulating agent (ESA), and intravenous iron dosing to achieved...
3.
Rodby R, Umanath K, Niecestro R, Bond T, Sika M, Lewis J, et al.
Drugs R D
. 2015 Aug;
15(3):271-9.
PMID: 26239948
Background: Patients with end-stage renal disease (ESRD) require phosphate binders for hyperphosphatemia and erythropoiesis-stimulating agents (ESAs) and intravenous (i.v.) iron for anemia. Ferric citrate (FC) is a novel, iron-based phosphate...
4.
Umanath K, Jalal D, Greco B, Umeukeje E, Reisin E, Manley J, et al.
J Am Soc Nephrol
. 2015 Mar;
26(10):2578-87.
PMID: 25736045
Ferric citrate (FC) is a phosphate binder with shown efficacy and additional effects on iron stores and use of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs). We provide detailed analyses...
5.
Rodby R, Umanath K, Niecestro R, Jackson J, Sika M, Lewis J, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2014 Dec;
15(3):545-50.
PMID: 25495878
Background: Ferric citrate (FC) is a new phosphorus binder shown to increase serum iron stores while reducing intravenous iron and erythropoiesis-stimulating agent usage. Such reductions could lower hospitalization rates and...
6.
Sinsakul M, Rodby R, Umanath K, Niecestro R, Dwyer J
Expert Rev Clin Pharmacol
. 2014 Sep;
7(6):705-10.
PMID: 25242077
Ferric citrate (Zerenex™, Keryx Biopharmaceuticals, Inc.), a phosphate binder drug candidate, recently completed a Phase III program confirming efficacy and demonstrating safety when used to treat hyperphosphatemia in patients with...
7.
Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury M, et al.
Hemodial Int
. 2012 Jun;
17(1):67-74.
PMID: 22702490
Chronic kidney disease associated mineral and bone disorders arise as a result of aberrant bone mineral metabolism in patients with advancing levels of renal dysfunction and end-stage renal disease. One...
8.
Weiss R, Niecestro R, Raz I
Drugs
. 2007 Dec;
67(18):2681-96.
PMID: 18062718
Diabetic nephropathy is an important cause of morbidity and mortality in patients with either type 1 or type 2 diabetes mellitus. The pathogenesis and natural history of diabetic nephropathy, characterised...
9.
Cullen E, Liao J, Lukacsko P, Niecestro R, Friedhoff L
Biopharm Drug Dispos
. 2004 Aug;
25(6):261-3.
PMID: 15334625
The pharmacokinetics and dose-exposure relationship of an extended-release formulation of metformin (ER-metformin) was investigated in a randomized, single-dose, four-period crossover study in 24 healthy male volunteers. During each study period,...
10.
Davidson M, Lukacsko P, Sun J, Phillips G, Walters E, Sterman A, et al.
Clin Ther
. 2002 Feb;
24(1):112-25.
PMID: 11833826
Background: Because lovastatin is efficiently extracted by the liver and because its administration in divided doses is associated with increased efficacy, an extended-release (ER) formulation may have the potential for...